BACKGROUND: Oral drugs have made the treatment of pulmonary hypertension (PH) feasible in nonexpert centers, which could delay patient access to prostanoid therapy. METHODS: Fifty-seven consecutive patients with precapillary PH received a prostanoid in our center. Data at prostanoid initiation included modality of center referral, medical history, New York Heart Association [NYHA] class, exercise capacity, echocardiographic parameters, and hemodynamics. RESULTS: Overall survival at 1, 2, and 3 years was 85%, 69%, 55%, respectively. Non-survivors had worse NYHA class III/IV (17/12) than survivors (27/1; p 0.01) and exercise capacity on 6-minutewalk distance (254 114 vs 354 91 meters; p 0.01). Non-survivors were more frequently referred on oral therapy (83% vs 36%; p 0.01) and had a higher rate of urgent prostanoid treatment (69% vs 17%; p 0.0001). Multivariate analysis (hazard ratio [95% confidence interval]) found the independent prognostic factors were urgent prostanoid therapy (2.0 [1.1–3.9]) and NYHA class (3.5 [1.5– 8.2]). Survivors had a significant response to prostanoid, improving NYHA class from 2.8 0.4 to 2.3 0.5 (p 0.002), 6-minute walk distance from 354 91 to 426 82 meters (p 0.0001), and pulmonary hemodynamics (pulmonary artery pressure from 56 13 to 44 18 mm Hg [p 0.05]; cardiac index from 2.0 1.2 to 3.1 1.2 liters/min/m2 [p 0.002], and pulmonary vascular resistance from 17 10 to 8 6 WU [p 0.001]). CONCLUSIONS: Referral of patients on oral treatment to a tertiary PH center is delayed and significantly affects prognosis.

Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy. the impact of late referral / Badagliacca, Roberto; Pezzuto, B; Poscia, Roberto; Mancone, Massimo; Papa, S; Marcon, S; Valli, G; Sardella, Gennaro; Ferrante, Fabio; Iacoboni, Carlo; Parola, Daniela; Fedele, Francesco; Vizza, Carmine Dario; Pezzuto, Beatrice. - In: THE JOURNAL OF HEART AND LUNG TRANSPLANTATION. - ISSN 1053-2498. - STAMPA. - 31:4(2012), pp. 364-372. [10.1016/j.healun.2011.12.011]

Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy. the impact of late referral.

BADAGLIACCA, ROBERTO;POSCIA, ROBERTO;MANCONE, Massimo;Papa S;SARDELLA, Gennaro;FERRANTE, Fabio;IACOBONI, Carlo;PAROLA, Daniela;FEDELE, Francesco;VIZZA, Carmine Dario
;
PEZZUTO, BEATRICE
2012

Abstract

BACKGROUND: Oral drugs have made the treatment of pulmonary hypertension (PH) feasible in nonexpert centers, which could delay patient access to prostanoid therapy. METHODS: Fifty-seven consecutive patients with precapillary PH received a prostanoid in our center. Data at prostanoid initiation included modality of center referral, medical history, New York Heart Association [NYHA] class, exercise capacity, echocardiographic parameters, and hemodynamics. RESULTS: Overall survival at 1, 2, and 3 years was 85%, 69%, 55%, respectively. Non-survivors had worse NYHA class III/IV (17/12) than survivors (27/1; p 0.01) and exercise capacity on 6-minutewalk distance (254 114 vs 354 91 meters; p 0.01). Non-survivors were more frequently referred on oral therapy (83% vs 36%; p 0.01) and had a higher rate of urgent prostanoid treatment (69% vs 17%; p 0.0001). Multivariate analysis (hazard ratio [95% confidence interval]) found the independent prognostic factors were urgent prostanoid therapy (2.0 [1.1–3.9]) and NYHA class (3.5 [1.5– 8.2]). Survivors had a significant response to prostanoid, improving NYHA class from 2.8 0.4 to 2.3 0.5 (p 0.002), 6-minute walk distance from 354 91 to 426 82 meters (p 0.0001), and pulmonary hemodynamics (pulmonary artery pressure from 56 13 to 44 18 mm Hg [p 0.05]; cardiac index from 2.0 1.2 to 3.1 1.2 liters/min/m2 [p 0.002], and pulmonary vascular resistance from 17 10 to 8 6 WU [p 0.001]). CONCLUSIONS: Referral of patients on oral treatment to a tertiary PH center is delayed and significantly affects prognosis.
2012
epoprostenol; prostanoids; pulmonary arterial hypertension; survival; treprostinil
01 Pubblicazione su rivista::01a Articolo in rivista
Prognostic factors in severe pulmonary hypertension patients who need parenteral prostanoid therapy. the impact of late referral / Badagliacca, Roberto; Pezzuto, B; Poscia, Roberto; Mancone, Massimo; Papa, S; Marcon, S; Valli, G; Sardella, Gennaro; Ferrante, Fabio; Iacoboni, Carlo; Parola, Daniela; Fedele, Francesco; Vizza, Carmine Dario; Pezzuto, Beatrice. - In: THE JOURNAL OF HEART AND LUNG TRANSPLANTATION. - ISSN 1053-2498. - STAMPA. - 31:4(2012), pp. 364-372. [10.1016/j.healun.2011.12.011]
File allegati a questo prodotto
File Dimensione Formato  
Badagliacca_Prognostic_2012.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 972.06 kB
Formato Adobe PDF
972.06 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/434406
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 43
  • ???jsp.display-item.citation.isi??? 42
social impact